Clinical trial

A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

NCT01245166

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Acarbose Normalized identity: acarbose View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Metformin/Acarbose Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2010-11-01

PhasePHASE3

Conditions

The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mgunresolved

Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks inunresolved

Subjects With Type 2 Diabetes Mellitus.unresolved

Interventions

AcarboseDRUG · verified · RxNorm: acarbose

Metformin/AcarboseDRUG

Sponsors & collaborators

Lotus Pharmaceuticallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01245166 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.